CD4 and neoplasm: However, treatment with entinostat monotherapy was associated with a decreased proliferation (Ki67+) in CD4+ T cells and reduced proliferation in other T cell subsets from baseline in the overall study population including a decrease in Th2, Th0, Th9, and Th17 CD4+T cells (Supplementary Fig. 5b and Supplementary Data 3 and 4), which are known to negatively affect the anti-tumor response through cytokine and chemokine expression leading to multiple mechanisms of effector T cell inhibition.